Absci Corp

Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs and other information that is not historical information.

SEC original ↗Absci Corp — 10-Q Quarterly report10-QAug 11, 2026

treasuries 93,277 93,277 Total assets $ 98,399 $ 93,277 $ $ 191,676 December 31, 2025 Level 1 Level 2 Level 3 Total Assets Debt Securities: Money market funds $ 14,410 $ $ $ 14,410 U.

SEC original ↗Absci Corp — 10-Q Quarterly report10-QAug 11, 2026

Other income (expense) Interest expense Interest expense consists primarily of interest related to borrowings under our term debt and financed laboratory equipment.

SEC original ↗Absci Corp — 10-Q Quarterly report10-QAug 11, 2026

htm EX-99.1 Document Exhibit 99.1 Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025 cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half of 2028 Expanded ongoing collaboration with Almirall, with election of a second target focused on dermatological indications VANCOUVER, Wash.

SEC original ↗Absci Corp — Earnings release (8-K exhibit)EX-99Aug 12, 2025

Expanded ongoing AI Drug Discovery collaboration with Almirall with election of a second target focused on dermatological indications.

SEC original ↗Absci Corp — Earnings release (8-K exhibit)EX-99Aug 12, 2025

Progressing on key initiatives in strategic collaboration with AMD, with objective of scaling Absci's AI Drug Creation platform using AMD Instinct accelerators and ROCm software.

SEC original ↗Absci Corp — Earnings release (8-K exhibit)EX-99Aug 12, 2025

In January 2025, concurrent with this collaboration, AMD also made a $20 million strategic equity investment in Absci.

SEC original ↗Absci Corp — Earnings release (8-K exhibit)EX-99Aug 12, 2025

In July 2025, Absci raised an additional approximately $64 million in gross proceeds from an underwritten public offering of common stock and strategic utilization of the company's at-the-market facility.

SEC original ↗Absci Corp — Earnings release (8-K exhibit)EX-99Aug 12, 2025

Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.

SEC original ↗Absci Corp — Earnings release (8-K exhibit)EX-99Aug 12, 2025

No natural or synthetic antibody for HIV exists today because immune system cannot derive an antibody that is universally neutralizing against HIV Design challenge: create universally neutralizing HIV antibody by binding unique and conserved epitope within caldera of open conformation of gp120 to prevent HIV from entering host cells Numerous attempts to target this epitope have failed-previous efforts have identified antibodies, but none bind the caldera and none are universally neutralizing.

SEC original ↗Absci Corp — Presentation / slide deck (8-K exhibit)EX-99Aug 12, 2025

HIV-Caldera: Determine inputs and design D E N O V O D E S I G N HIV Env Trimer Challenge : Highly glycosylated Extremely high sequence diversity among isolates High mutation rate at common neutralizing epitopes Model inputs: 1.

SEC original ↗Absci Corp — Presentation / slide deck (8-K exhibit)EX-99Aug 12, 2025

Legal Proceedings 27 Item 1A.

SEC original ↗Absci Corp — 10-Q Quarterly report10-QAug 11, 2026

Our plans and expectations regarding the initiation, timing, progress, results, and costs of our internally developed programs and partnered programs, including current and future preclinical studies and clinical trials, and the period during which the results of such studies and trials will become available, are subject to a high degree of uncertainty.

SEC original ↗Absci Corp — 10-Q Quarterly report10-QAug 11, 2026

Our or our partners' preclinical and clinical product candidates may experience delays or may never advance to and/or through clinical trials, which would adversely affect our or our partners ability to obtain regulatory approvals or commercialize these product candidates on a timely basis or at all, which would have an adverse effect on our business.

SEC original ↗Absci Corp — 10-Q Quarterly report10-QAug 11, 2026